The board of directors of Beijing Luzhu Biotechnology Co., Ltd. announced that LZ901, the core product of the Group, has completed the enrollment of subjects for its Phase III clinical trial in the People's Republic of China (the "PRC"), and more than 98% subjects have received two doses of LZ901 injection or placebo injection, as the case may be. The Phase III clinical trial will now proceed to case collection, and will proceed to interim unblinding work of the trial data after the primary endpoints of the trial are being met. The Phase III clinical trial is a multi-center, randomized, double-blind, placebo-controlled parallel study to evaluate the efficacy and safety profile of LZ901 for the prevention of herpes zoster in adults aged 40 years and older.

The study is conducted in four provinces including Jiangsu, Shandong, Hubei and Shanxi, with a total enrollment of 26,000 healthy subjects aged 40 years and older as of the date of this announcement.